Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.62 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7439701 | 0.86 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL432016 | 0.85 | TSHR (0.62) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL27630437 | 0.85 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL29415167 | 0.84 | MAPK1 (0.77) | ALDH1A1CYP1A2CYP2C19TSHRHTT | |
| SCHEMBL335681 | 0.84 | MAPK1 (0.77) | ALDH1A1CYP1A2CYP2C19TSHRHTT | |
| SCHEMBL313116 | 0.83 | ALDH1A1 (0.76) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL31652866 | 0.83 | ALDH1A1 (0.76) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| SCHEMBL36091 | 0.83 | ALDH1A1 (0.76) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD | |
| Hydrochloric Acid SCHEMBL5154533 | 0.82 | MAPK1 (0.74) | ALDH1A1CYP1A2CYP2C19TSHRHTT | |
| SCHEMBL29810107 | 0.81 | ALDH1A1 (0.73) | ALDH1A1CYP1A2CYP2C19CYP2D6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805267-B | Carboxamide and sulfonamide derivatives as TEAD modulators | 豪夫迈·罗氏有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-3847154-A1 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | F. Hoffmann-La Roche AG (CH) | 2021-07-14 | — | — | EP | disclosed |
| CN-108586500-B | Zinc coordination complex and method for preparing organic zinc reagent | 慕尼黑路德维希马克西米利安斯大学 | 2021-06-25 | — | — | CN | disclosed |
| US-20210188775-A1 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | GENENTECH, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| CN-112805267-A | Carboxamide and sulfonamide derivatives as TEAD modulators | 豪夫迈·罗氏有限公司 | 2021-05-14 | — | — | CN | disclosed |
| EP-3272754-B1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2019-05-29 | — | — | EP | disclosed |
| EP-3272754-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| CN-104321325-B | Pyrrolopyrrole alkanone compound | 诺华股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| EP-3064502-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| CN-104321325-A | Pyrrolopyrrolidinone compounds | NOVARTIS AG | 2015-01-28 | — | — | CN | disclosed |
| EP-2807164-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20140343084-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8815926-B2 | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| WO-2014008214-A1 | BIARYL-CONTAINING COMPOUNDS AS INVERSE AGONISTS OF ROR-GAMMA RECEPTORS | BIOGEN IDEC MA INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2014008214-A1 | BIARYL-CONTAINING COMPOUNDS AS INVERSE AGONISTS OF ROR-GAMMA RECEPTORS | BIOGEN IDEC MA INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013111105-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-6071927-A | Spiro-piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2000-06-06 | — | — | US | disclosed |
| EP-0906315-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997049710-A1 | SPIRO-PIPERIDINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | MDM4, MDM2, TP53 | ALDH1A1 2047/4885CYP1A2 2781/4885CYP2C19 2949/4885 |
| US-20140343084-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | MDM4, MDM2, TP53 | ALDH1A1 2047/4885CYP1A2 2781/4885CYP2C19 2949/4885 |
| US-20210188775-A1 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | TEAD2, TEAD1, SULT2A1 | ALDH1A1 441/4885CYP1A2 235/4885CYP2C19 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.